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Abstract 
Background: Myocardial fibrosis is an important prognostic factor in hypertrophic cardiomyopathy (HCM). However, 
the contribution from a wide spectrum of genetic mutations has not been well defined. We sought to investigate 
effect of sarcomere and mitochondria‑related mutations on myocardial fibrosis in HCM.
Methods: In 133 HCM patients, comprehensive genetic analysis was performed in 82 nuclear DNA (33 sarcomere‑
associated genes, 5 phenocopy genes, and 44 nuclear genes linked to mitochondrial cardiomyopathy) and 37 
mitochondrial DNA. In all patients, cardiovascular magnetic resonance (CMR) was performed, including 16‑segmental 
thickness, late gadolinium enhancement (LGE), native and post‑T1, extracellular volume fraction (ECV), and T2, along 
with echo‑Doppler evaluations.
Results: Patients with sarcomere mutation (SM, n = 41) had higher LGE involved segment, % LGE mass, ECV and 
lower post‑T1 compared to patients without SM (n = 92, all p < 0.05). When classified into, non‑mutation (n = 67), only 
mitochondria‑related mutation (MM, n = 24), only‑SM (n = 36) and both SM and MM (n = 5) groups, only‑SM group 
had higher ECV and LGE than the non‑mutation group (all p < 0.05). In non‑LGE‑involved segments, ECV was signifi‑
cantly higher in patients with SM. Within non‑SM group, patients with any sarcomere variants of uncertain signifi‑
cance had higher echocardiographic Doppler E/e’ (p < 0.05) and tendency of higher LGE amount and ECV (p > 0.05). 
However, MM group did not have significantly higher ECV or LGE amount than non‑mutation group.
Conclusions: SMs are significantly related to increase in myocardial fibrosis. Although, some HCM patients had 
pathogenic MMs, it was not associated with an increase in myocardial fibrosis.
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Background
Myocardial fibrosis, especially replacement fibrosis, is an 
important prognostic factor in hypertrophic cardiomyo-
pathy (HCM) [1]. It causes lethal ventricular arrhythmia, 
exercise intolerance due to decreased ventricular compli-
ance, atrial fibrillation, and progression to left ventricular 
(LV) systolic dysfunction. Although validated pathogenic 
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sarcomere gene mutations (SMs) are the primary con-
tributors to LV hypertrophy, a wide spectrum of genetic 
mutations, a sarcomere variant of uncertain significance 
(VUS) [2], and phenocopy gene and mitochondria-
related mutations (MM) [3] also have been shown to be 
associated with HCM [4]. However, their degrees of con-
tribution to myocardial fibrosis have yet to be extensively 
investigated.
Previous studies showed that pathogenic or likely 
pathogenic SMs are related to a higher prevalence and 
amount of LV fibrosis measured by cardiovascular mag-
netic resonance (CMR) late gadolinium enhancement 
(LGE) and native T1 mapping [5–8]. However, the results 
were controversial, especially in non-LGE segments, due 
to the limited number of patients, candidates of genetic 
mutations (e.g., only MYBPC3 or MYH7), or techniques 
for myocardial tissue characterization. Recently, patients 
with sarcomere VUS were reported as having worse prog-
nosis than the mutation negative patients [9]. Moreover, 
several basic science and translational studies suggest 
that MM (nuclear or mitochondrial DNA) are related to 
HCM and arrhythmic events [10]. We also recently pub-
lished that MM were related to apical hypertrophy, a rel-
atively benign phenotype, in a Korean population [11].
Regarding accurate myocardial tissue characteriza-
tion, LGE is a validated method for replacement fibrosis. 
However, the pathological finding of HCM is complex 
and consists of myocyte disarray, diffuse or conglomer-
ated replacement fibrosis, and intramyocardial small ves-
sel fibrosis. Thus, LGE alone is not sufficient to show all 
pathological changes in HCM. With the recently devel-
oped T1/T2 mapping techniques conjoined with extra-
cellular gadolinium distribution, CMR could make it 
possible to measure extracellular volume fraction (ECV) 
and the degree of myocardial inflammation. One of the 
strengths of the T1/T2 mapping technique is that it pro-
vides the degree of interstitial fibrosis and inflammation 
in the remote myocardium or gray zone in LGE imaging. 
Therefore, this technique would provide tissue character-
ization in healthy looking regional myocardium, in addi-
tion to the global LGE amount.
To overcome these limitations, we investigated the 
relationship between genetic mutations and myocardial 
tissue characteristics using extensive targeted genetic 
analysis in nuclear DNA (nDNA) and mitochondrial 
DNA (mtDNA). For accurate tissue characterization of 
LV myocardium, global and American  Heart  Associa-
tion 16-segmental thickness, LGE amount, ECV, native 
T1, post-contrast T1, and T2 values were measured using 
CMR in HCM patients.
Methods
Study population
Of the 212 HCM patients who were enrolled in genetic 
study [11], 133 underwent CMR with LGE and T1/T2 
mapping. The patients enrolled in the study had maximal 
LV hypertrophy greater than 13 mm and a ratio of maxi-
mal thickness to inferolateral wall thickness greater than 
1.3 without an underlying cause of hypertrophy, such as 
uncontrolled hypertension or aortic stenosis. Both the 
pure apical type (hypertrophy confined below the papil-
lary muscle level) and the mixed type (apical hypertrophy 
combined with asymmetrical septal hypertrophy at the 
mid-LV level, but with maximal thickness in the apex) 
were categorized as apical HCM [12]. All patients under-
went screening analysis for Anderson-Fabry disease and 
were confirmed negative for the galactosidase alpha vari-
ant. The study protocol was approved by our institutional 
review board (3-2015-0019), and written informed con-
sent was obtained from each participant.
Genetic testing and analysis
HCM gene panel design for nDNA and mtDNA
A literature search of the PubMed database was per-
formed to select targeted genes for the comprehensive 
HCM-specific gene panel, and 82 nDNA genes were 
included: 33 sarcomere protein genes, 5 phenocopy 
genes, and 44 nuclear genes linked to mitochondrial car-
diomyopathy. HCM genes consisted of 8 validated sar-
comere genes and 25 putative HCM genes [4, 11].
DNA preparation, library construction and sequencing 
of the HCM gene panel and mtDNA
Data analysis of the HCM gene panel and mitochondrial 
genome [11] The details are described in Additional 
file 1: Method S1.
Classification of pathogenic/likely pathogenic variants 
and VUS
For 33 HCM genes, annotated variants using ANNOVAR 
and Variant Effect Predictor were classified as patho-
genic, likely pathogenic, VUS, likely benign or benign 
based on refined American College of Medical Genet-
ics and Genomics (ACMG) standards and guidelines for 
inherited cardiac conditions [13]. For 44 mitochondria-
related  nDNA genes (recessive conditions), annotated 
variants were classified as pathogenic and likely patho-
genic based on ACMG guidelines. And we adapted gno-
mAD AF cutoff 0.01% as the moderate level of evidence 
supporting pathogenicity (ACMG/AMP criterion PM2) 
based on maximum credible population AF [13].
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Identification of potential pathogenic mtDNA variants
Non-haplogroup-associated novel and rare variants were 
evaluated for potential pathogenicity based on variant 
location, amino acid change, and evolutionary conserva-
tion [14]. We interpreted mitochondrial variants using 
mitochondrial genome databases. We have assessed 
potential pathogenicity of novel and rare non-haplogroup-
associated variants using multiple software programs 
including Polyphen2, Fathmmw, Mutation Assessor, and 
PROVEAN. When the majority of computational evi-
dence supported a deleterious effect, we have assigned 
novel and rare non-haplogroup-associated variants as 
damaging mtDNA variants. Clinically relevant variants 
in mitochondrial genome databases and probably damag-
ing nonsynonymous mtDNA variants in silico prediction 
were considered damaging mtDNA variants. The mito-
chondria-related deleterious variations (MM) consisted 
of damaging variants of mtDNA and likely pathogenic/
pathogenic mutations of mitochondrial-nDNA. [11].  To 
evaluate systemic involvement in mitochondrial dysfunc-
tion, 19 questions were answered by all subjects. Detailed 
questions are described in Additional file 1: Method S2.
Echocardiographic analysis
The details are described in Additional file 1: Method S3.
Cardiovascular magnetic resonance imaging
CMR was performed using a 1.5-T CMR scanner (Mag-
netom Avanto; Siemens Healthineers, Erlangen, Germany) 
with a phased array body coil. The LV 2-, 3-, 4-chamber, and 
short-axis views were obtained using cine images with bal-
anced steady-state free precession (bSSFP) sequence. LGE 
imaging was obtained 10 min after injection after adminis-
tration of a gadolinium-based contrast agent (0.2  mmol/kg 
gadoterate dimeglumine; Dotarem, Guerbet, Paris, FR) with 
a fast gradient echo sequence prepared with magnitude- and 
phase-sensitive inversion recovery (PSIR). A bolus of contrast 
media was intravenously administered at 2 mL/s, followed by 
20 mL normal saline at 4 mL/s through a 20-gauge cannula in 
the antecubital vein using a power injector (Nemoto; Nemoto 
Kyorindo, Tokyo, Japan). The appropriate inversion time 
before LGE imaging was determined using a fast gradient 
echo sequence with varied inversion times (150–650 ms) to 
null the signal from the normal myocardium. The following 
LGE imaging parameters were used: TR, 8.8 ms; TE, 3.36 ms; 
flip angle, 25°; acquisition matrix, 256 × 166; and field of view, 
276 × 340 mm. Native T1 mapping with a modified Look-
Locker inversion recovery (MOLLI) technique was per-
formed during the mid-diastolic phase, and post-T1 mapping 
was performed 15 min after contrast media injection using 
the same slice axis and parameters as the pre-T1 mapping 
[15]. Quantitative T2 mapping imaging was performed 
before contrast media injection with a T2-prepared bSSFP 
pulse sequence along the same short-axis planes used for cine 
imaging. A motion correction algorithm provided by the ven-
dor was used to reduce motion artifacts. The following acqui-
sition parameters were used for T2 mapping: T2 preparation 
times, 0, 24, and 55 ms; TR, 3 × R-R ms; acquisition matrix, 
126 × 192; acquisition time, 7 × R-R; single-shot acquisition; 
flip angle, 70°; and bandwidth, 916 Hz/pixel. T2-pixel maps 
were generated after motion correction using commercially 
available software on the scanner’s workstation (Syngo; Sie-
mens Healthineers) [16]. The LV was divided into 16 regional 
segments according to American Heart Association guide-
lines, and the average thickness within each segment was 
measured [17]. In the regional analysis, the anteroseptum was 
defined as segments 1, 2, 3, 7, 8, 9, 13, and 14; septum, as 2, 3, 
8, 9, and 14; inferoposterior segment, as 4, 5, 10, 11, and 15; 
lateral segment, as 6, 11, and 16; and apical segment, as 13, 14, 
15, and 16.
Measurement of late gadolinium enhancement
The presence of LGE involvement in each segment and the 
total number of LGE-involving segments were determined. 
In addition, the pattern of LGE and the percentage of LGE 
in LV mass were measured using dedicated quantitative 
analysis software (QmassMR 7.5 or 8.1, Medis Medical 
Imaging, Leiden, The Netherland) on PSIR LGE images [16]. 
To improve the reproducibility, a radiologist and a cardiolo-
gist, each with more than 10 years of experience analyzed 
LGE data. In each short-axis slice image, boundaries of con-
trast-enhanced areas were automatically traced. On LGE-
CMR images, myocardium with abnormal enhancement 
was defined as an area of hyperenhancement more than 5 
standard deviations from the remote myocardium. Remote 
myocardium was defined as nonenhanced myocardium, the 
opposite of hyperenhanced myocardium [18]. The maxi-
mal signal was determined by computer-assisted window 
thresholding of the enhanced area. Obvious artifacts, such 
as those caused by motion, were excluded using a tool from 
the software package. Total LGE volume was calculated by 
summing the LGE volumes of all the slices [19].
Measurement of native T1, extracellular volume fraction, 
and T2
With QMap and QECV-RE (Medis Medical Imaging), T2, 
native T1 (n = 128), post-T1, and ECV (n = 125) analyses 
were performed in the 128 patients. The myocardial ECV 
was automatically calculated with the following equation:
ECV = (�R1 of myocardium/�R1 of LV blood pool)× (1− hematocrit),
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where R1 = 1 / T1 and  R1 = post-contrast R1 − pre-
contrast R1 [20].
For normal control, we enrolled four healthy sub-
jects and analyzed their ECVs. As a positive control, 
ECVs were analyzed in eight subjects who underwent 
CMR with T1 mapping for the evaluation of the cause 
of aborted sudden cardiac death or idiopathic ventricu-
lar tachycardia but had normal LV systolic function and 
structure both on echocardiography and CMR.
Statistical analysis
Continuous variables with normal distributions are 
reported as the mean ± standard deviation or 95% con-
fidence intervals. Student’s t-tests were used to compare 
the means of continuous variables that were approxi-
mately normally distributed between the two groups. 
Normality was determined using the Shapiro–Wilk test. 
Categorical variables are reported as counts (or percent-
ages) and were compared using chi-square tests. For 
comparisons of more than two groups, analysis of vari-
ance was performed with post-hoc analysis (Fisher’s least 
squares difference test) for subgroup comparison. For 
the multivariable analysis, a linear regression analysis 
was performed to check the independence of the vari-
ables. All statistical analyses were performed using SPSS 
(version 25.0, Statistical Package for the Social Sciences, 
International Business Machines, Inc., Armonk, New 




The mean age of the 133 participants was 58 ± 13 years, 
and 35 (26%) of them were female. 34 (26%) had obstruc-
tive HCM, and 66 (50%) had apical pHCM. Of those with 
apical HCM, 43 (65%) participants had pure-type apical 
HCM. Based on ACMG guidelines [21], 41 (31%) par-
ticipants had 43 pathogenic or likely pathogenic SMs (19 
MYBPC3, 12 MYH7, 8 TNNI3, 2 MYH6, 1 JPH2, and 1 
TNNC1). Two patients harbored more than one SMs 
(one had MYBPC3 and MYH7; another had MYBPC3 
and JPH2). In total, 18 (14%) patients had a probably 
damaging mtDNA variant, and 11 (8%) had a patho-
genic or likely pathogenic mitochondria-related nDNA 
variant. Six patients (5%) had both pathogenic or likely 
pathogenic SM and pathogenic MM. Of the 92 non-SM 
patients, 32 (35%) had any sarcomere VUS (Additional 
file  2: Table  S1). The SM group included more women 
and had a lower prevalence of apical HCM and a higher 
prevalence of atrial fibrillation, as well as greater left atrial 
(LA) volume index, maximal LV thickness, and 5-year 
sudden cardiac death risk compared with non-SM group. 
Within non-SM group, patients with sarcomere VUS 
had higher echocardiographic Doppler E/e’ than oth-
ers (Table 1). Age, sex, LA volume index, LV mass index, 
resting LV outflow tract gradient, percent LGE mass, LGE 
segment number, and global native and post-contrast 
T1 were significantly correlated with echocardiographic 
Table 1 Comparison of  clinical and  echo-Doppler findings between  the  sarcomere gene mutation group and  the  non-
mutation group
AF atrial fibrillation, HCM hypertrophic cardiomyopathy, E early diastolic transmitral inflow velocity, e’ early diastolic mitral annular velocity, LA left atrial, SCD sudden 
cardiac death, VUS variant uncertain significance
All HCM Absence of pathogenic/likely 
pathogenic sarcomere gene 
mutation group
Presence of sarcomere 
gene mutation group 
(n = 41)
Absence of sarcomere gene 
mutation group (n = 92)
P Sarcomere





Age, years 55.9 ± 13.5 59.6 ± 12.8 0.137 60.0 ± 12.5 59.4 ± 13.1 0.807
Women, n (%) 16 (39) 19 (21) 0.026 8 (25) 11 (18) 0.589
Hypertension, n (%) 281 (51) 39 (42) 0.345 15 (47) 24 (40) 0.658
Diabetes, n (%) 7 (17) 19 (21) 0.631 7 (22) 12 (20) > 0.999
Persistent AF at echo, n (%) 9 (22) 7 (8) 0.019 3 (9) 4 (7) 0.691
Apical HCM, n (%) 13 (32) 53 (58) 0.006 14 (44) 39 (65) 0.076
Dynamic obstruction, n (%) 7 (17) 27 (29) 0.134 10 (31) 17 (28) 0.813
LA volume index, mL/m2 41.2 ± 17.6 32.4 ± 11.3 0.005 35.2 ± 12.8 31.0 ± 10.2 0.109
Echo Doppler E/e’ 15.4 ± 7.3 14.6 ± 5.3 0.454 16.3 ± 5.6 13.7 ± 5.0 0.036
Maximal thickness, mm 19.9 ± 3.7 18.4 ± 3.6 0.032 18.5 ± 3.3 18.4 ± 3.8 0.911
5‑year SCD risk (n = 83), % 2.8 ± 1.5 1.9 ± 1.8 0.029 2.4 ± 3.0 1.7 ± 0.6 0.214
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Doppler E/e’ (all P < 0.05). Among them, resting LV out-
flow tract gradient (β = 0.286; P < 0.001) and LGE seg-
ment number (β = 0.195; P = 0.037) were independently 
related to Doppler E/e’. The mitochondrial questionnaire 
score was not significantly different between the MM 
group and others. The age of normal control and positive 
control was 31 ± 2  years and 38 ± 19  years, respectively 
and their average 16-segmental ECV was 25.2 ± 1.6% 
and 29.3 ± 5.9% (average mid-ventricular ECV was 
24.7 ± 2.4% and 28.4 ± 5.8%, respectively) was signifi-
cantly lower than HCM patients (p < 0.001).
Pathogenic sarcomere mutations on global and segmental 
LGE, ECV, and T2
No significant difference in LV mass was found between 
the SM and the non-SM groups. However, the regional 
anteroseptal wall was significantly thicker in the SM 
group (13.2 ± 2.6  mm vs. 12.0 ± 3.4; P = 0.018), whereas 
the lateral wall was thicker in the non-SM group. 
Patients with pathogenic or likely pathogenic SMs had 
a higher prevalence of LGE (90% vs. 60%; P < 0.001) and 
more LGE-involved segments (4.9 ± 2.8 vs. 2.9 ± 3.5; 
P = 0.002) than patients without SM. The SM group 
had significantly higher global ECV than the non-SM 
group (34.2 ± 4.8% vs. 31.4 ± 4.3%; P = 0.001). In par-
ticular, the SM group had significantly higher ECV in 
septal segments (35.7 ± 6.7% vs. 31.4 ± 4.1%; P < 0.001) 
and anteroseptal segments (35.8 ± 6.8% vs. 31.8 ± 4.4%; 
P = 0.001) (Fig. 1). In addition, the SM group had shorter 
global and anteroseptal segment post-contrast T1 than 
the non-SM group. However, no difference in native T1 
and T2 values were found between the SM and non-SM 
groups (Table  2). When analyzed in segments without 
LGE involvement, the SM group had significantly higher 
global (32.4 ± 3.8% vs. 30.7 ± 3.9%, P = 0.025), septal 
(33.3 ± 4.6% vs. 31.0 ± 3.9%; P = 0.006), anteroseptal, and 
inferoposterior ECV than the non-SM group (all P < 0.05; 
Fig. 1).
Effect of individual sarcomere, mitochondria‑related 
mutations and VUS on myocardial fibrosis
Although patients with pathogenic or likely pathogenic 
MYH7 mutations tended to have higher %LGE and 
ECVs than those with MYBPC3 or other SMs, this differ-
ence did not reach significance (Fig. 2). Detailed genetic 
alterations of detected sarcomere-associated genes, 
mitochondria-related nDNAs and damaging mtDNA 
variants are shown in Additional file 2: Tables S2 and S3. 
Known pathogenic mtDNA variants were detected from 
only four patients and were not present with extracar-
diac features of mitochondrial disease such as diabetes, 
deafness and etc. When classified into non-mutation 
(n = 67), only MM (n = 24), only-SM (n = 36), and both 
SM and MM (n = 5) groups (one patient was missed due 
Fig. 1 a Comparison of late gadolinium enhancement (LGE) involvement and extracellular volume fraction (ECV) between pathogenic or likely 
pathogenic sarcomere gene mutation (SM) group and non‑SM group in all segments. b Comparison of global and septal ECV between SM group 
and non‑SM group in segments without LGE
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Table 2 Comparison of  cardiovascular magnetic resonance imaging findings between  the  sarcomere gene mutation 
group and the non-mutation group
LV left ventricular, LVEDV LV end-diastolic volume, LVESV LV end-systolic volume
Presence of sarcomere gene mutation group 
(n = 41)
Absence of sarcomere gene mutation group 
(n = 92)
P
LVEDV, mL 133.6 ± 28.6 135.7 ± 28.2 0.698
LVESV, mL 51.7 ± 23.1 46.9 ± 18.5 0.208
LV mass, g 153.7 ± 37.2 152.8 ± 48.0 0.913
LV mass index, g/m2 88.0 ± 21.1 84.7 ± 23.8 0.456
LV mass/volume ratio 1.19 ± 0.32 1.14 ± 0.32 0.469
LV ejection fraction, % 62.5 ± 9.4 65.7 ± 9.8 0.077
Segmental* thickness, mm
Thickness in anteroseptal segments 13.0 ± 2.9 11.7 ± 3.2 0.025
Thickness in septal segments 14.4 ± 3.4 12.5 ± 3.6 0.005
Thickness in inferoposterior segments 8.6 ± 2.1 8.9 ± 1.8 0.484
Thickness in lateral segments 7.6 ± 2.2 8.6 ± 2.1 0.020
Thickness in apical segments 10.5 ± 3.2 10.7 ± 3.9 0.771
Late gadolinium enhancement (LGE)
Presence of LGE in LV, n (%) 37(90) 55(60)  < 0.001
Number of LGE segments in LV 4.9 ± 2.8 2.9 ± 3.5 0.002
% LGE amount of LV 10.6 ± 10.1 6.4 ± 9.3 0.040
LGE in anteroseptal segments, % 46.3 ± 25.7 20.7 ± 26.2  < 0.001
LGE in septal segments, % 47.8 ± 30.0 18.0 ± 26.2  < 0.001
LGE in inferoposterior segments, % 7.8 ± 14.8 13.5 ± 24.5 0.609
LGE in lateral segments, % 16.6 ± 20.4 14.4 ± 24.3 0.171
LGE in apical segments, % 36.0 ± 37.9 29.1 ± 37.5 0.331
T2, ms
T2 average of 16 segments 56.1 ± 3.5 55.3 ± 3.0 0.177
T2 in anteroseptal segments 56.9 ± 3.7 55.3 ± 3.0 0.242
T2 in septal segments 57.9 ± 4.0 57.2 ± 3.7 0.360
T2 in inferoposterior segments 55.9 ± 3.7 54.8 ± 3.3 0.117
T2 in lateral segments 54.9 ± 4.0 54.0 ± 3.3 0.193
T2 in apical segments 57.1 ± 5.6 56.7 ± 4.3 0.677
Native T1, ms
T1 average of 16 segments 1025 ± 47 1019 ± 49 0.512
T1 in anteroseptal segments 1023 ± 46 1017 ± 51 0.524
T1 in septal segments 10343 ± 44 1024 ± 49 0.301
T1 in inferoposterior segments 1045 ± 59 1032 ± 54 0.216
T1 in lateral segments 1014 ± 59 1013 ± 54 0.921
T1 in apical segments 1009 ± 66 1017 ± 58 0.469
Post contrast T1, ms
T1 average of 16 segments 579 ± 59 607 ± 63 0.021
T1 in anteroseptal segments 569 ± 66 603 ± 64 0.008
T1 in septal segments 574 ± 66 608 ± 63 0.007
T1 in inferoposterior segments 595 ± 53 616 ± 63 0.065
T1 in lateral segments 590 ± 56 611 ± 65 0.085
T1 in apical segments 564 ± 57 588 ± 66 0.051
Extracellular volume fraction (ECV), %
ECV average of 16 segments 34.2 ± 4.8 31.4 ± 4.3 0.001
ECV in anteroseptal segments 35.8 ± 6.8 31.8 ± 4.4 0.001
ECV in septal segments 35.7 ± 6.7 31.4 ± 4.1  < 0.001
ECV in inferoposterior segments 32.7 ± 4.0 30.8 ± 4.5 0.022
ECV in lateral segments 31.8 ± 3.9 30.7 ± 5.1 0.235
ECV in apical segments 35.3 ± 4.6 33.7 ± 5.5 0.118
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to non-analysis of mtDNA), only-SM group had higher 
amount of LGE and ECV compared to non-mutation 
group and only-MM group (all p < 0.05). The MM-only 
group was not significantly different from the non-muta-
tion group (Table 3; Fig. 3; Additional file 2). For the non-
SM group, patients with sarcomere VUS demonstrated 
a trend for a higher %LGE and ECV (Additional file  2: 
Table S4).
Discussion
This study confirmed that pathogenic or likely patho-
genic SMs are significantly related to higher amounts of 
LV replacement fibrosis and ECV, especially in the sep-
tal area. This finding supports that worse outcomes in 
patients with HCM are related to SMs. Even in segments 
without LGE, ECV was significantly higher in patients 
with pathogenic or likely pathogenic SMs. Within non-
SM group, patients with any sarcomere VUS had higher 
Doppler E/e’ and tendency of higher fibrosis. However, 
MMs were not related to increased myocardial fibrosis.
Sarcomere mutation and myocardial fibrosis
In a previous study by Ellims, although patients with 
SMs had higher LGE amounts, they had longer post-T1 
than those without SMs, especially in non-LGE segments 
[6]. This result differed from that of other studies [2, 7]. 
In our study, patients with SMs had higher ECV than 
those without SM—not only globally and regionally in 
the septum but also in lateral and inferolateral segments 
where LGE involvement is rare. These results suggest 
higher amounts of diffuse interstitial fibrosis in patients 
with SM, which is consistent with other studies [2, 7, 8]. 
Regarding SM related worse phenotypes, the NHLBI 
HCM registry results reported that SM was more likely 
to have reverse septal curvature morphology, LGE, and 
no significant resting LV outflow tract obstruction, while 
those that were SM negative were more likely to have 
isolated basal septal hypertrophy, less LGE, and more LV 
outflow tract obstruction [7]. Our study adds a new evi-
dence of higher prevalence of apical type HCM, known 
as benign phenotype in SM negative group. Our study 
results are compatible with the previous studies that 
SM positive group has higher amount of replacement 
fibrosis and interstitial fibrosis[7], even in non-LGE seg-
ments, which supports worse prognosis, especially for 
significant arrhythmic events due to potential substrates 
for reentry circuit due to tissue heterogeneity [8, 9]. In 
addition, we found that Doppler E/e’ was significantly 
correlated with LGE (both %LGE and the number of 
LGE-involved segments), as well as regional ECV (septal 
and anteroseptal segments). A previous study revealed 
that a sarcomere gene (MYH7) mutation, induces profi-
brotic change and fibrosis through activation of TGF-β 
signaling in non-myocyte cells of mice myocardium [22]. 
It suggested that myocardial fibrosis would be a pri-
mary phenotype of sarcomere mutations, which is also 
supported by our study results, in terms of replacement 
fibrosis (LGE) and interstitial fibrosis (ECV). Interest-
ingly, within non-SM group, patients with VUS had 
higher E/e’ and tendency of higher LGE amount and 
ECV, which supports a previous study results of worse 
Fig. 2 Comparisons of global percent LGE mass (a), LGE‑involved segment number (b), T2 (c), native T1 (d), post contrast T1 (e), and ECV (f) among 
individual sarcomere variants
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prognosis. But it needs further investigation with large 
number of population [9]. However, the T2 value was not 
significantly different among genetic-based subgroups, 
suggesting that occult myocardial inflammation is not a 
primary phenotype in HCM. One also has to recognize 
that absence of known SM does not mean that there is 
no mutation, it only means the mutation in the patient 
has not been broadly identified or recognized as a likely 
disease causing mutation.
Mitochondria‑related mutations and myocardial fibrosis
Basic science studies have shown that MMs induce pro-
arrhythmic effects and myocardial dysfunction, espe-
cially in diastolic function [23]. However, no studies 
have observed the effect of MM on myocardial fibrosis. 
According to our study results, some patients had path-
ogenic MMs in patients without SM or with SM. How-
ever, patients with MM in the non-SM group exhibited 
no significant differences in clinical parameters, degree 
of replacement fibrosis, or diffuse interstitial fibrosis and 
inflammation (as reflected by LGE, ECV, and T2 values) 
from those without any mutations.
Regarding whether MMs have additive effects with 
SMs on myocardial fibrosis, patients with both sar-
comere and mitochondria-related mutations tended to 
have higher ECVs. However, no significant difference 
was seen, possibly due to the subgroup’s small size (5% 
of the entire sample). This result suggests that a MM has 
benign phenotypic characteristics or does not contribute 
Table 3 Comparison of  cardiac magnetic resonance imaging findings between  the  sarcomere gene and  mitochondria-
related gene mutation groups
One patient was missed due to non-analysis of mtDNA
a Pathogenic or likely pathogenic mitochondria-related nDNA mutations or damaging mtDNA variants
* P < 0.05
**P < 0.01 versus no pathogenic or likely pathogenic variant group
† P < 0.05
†† P < 0.01 versus mitochondria-related variant group
No pathogenic or likely 
pathogenic variant 
group (n = 67)
Only mitochondria‑
related nDNA or mtDNA 
variant  groupa (n = 24)
Only sarcomere gene 
variant group (n = 36)
Sarcomere 
and mitochondria‑
related gene variant 




Presence of LGE in left 
ventricle
42 (61) 12 (50) 32 (89) 5 nn 0.003
Number of LGE segments 
in left ventricle
2.9 ± 3.3 2.6 ± 3.8 5.0 ± 2.9**,†† 4.2 ± 1.1 0.012
% LGE amount of left 
ventricle
6.4 ± 7.8 8.1 ± 13.0 10.9 ± 10.7* 8.3 ± 3.6 0.184
LGE in anteroseptal seg‑
ments, %
20.9 ± 24.9 17.7 ± 28.1 47.2 ± 27.2**,†† 40.0 ± 5.6†  < 0.001
LGE in septal segments, % 18.2 ± 24.8 15.0 ± 27.8 48.3 ± 31.5**,†† 44.0 ± 16.7*,††  < 0.001
LGE in inferoposterior seg‑
ments, %
12.8 ± 23.8 15.0 ± 27.2 7.8 ± 14.6 8.0 ± 17.9 0.826
LGE in lateral segments, % 15.2 ± 25.4 11.7 ± 22.0 17.2 ± 20.9 12.0 ± 17.9 0.580
LGE in apical segments, % 28.4 ± 37.7 28.1 ± 35.6 37.5 ± 39.4 25.0 ± 25.0 0.643
Extracellular volume fraction 
(ECV), %
ECV average of 16 seg‑
ments
31.5 ± 4.3 30.9 ± 4.5 34.0 ± 5.0*,† 35.4 ± 3.4† 0.013
ECV in anteroseptal seg‑
ments
31.9 ± 4.2 31.4 ± 5.0 35.6 ± 7.0**,†† 36.9 ± 5.2*,† 0.002
ECV in septal segments 31.6 ± 3.9 30.7 ± 4.8 35.6 ± 6.9**,†† 36.8 ± 5.8*,†  < 0.001
ECV in inferoposterior 
segments
31.0 ± 4.6 30.2 ± 4.0 32.4 ± 4.1 34.8 ± 2.7† 0.065
ECV in lateral segments 30.9 ± 5.2 30.0 ± 4.8 31.7 ± 4.1 32.4 ± 1.8 0.544
ECV in apical segments 33.7 ± 5.2 33.7 ± 6.4 35.3 ± 4.8 35.5 ± 4.3 0.500
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to phenotypic expressions because of recessive heritance 
and heteroplasmy of mtDNA mutations [10]. In addi-
tion, it suggests that SM, not MM, contributes to the 
primary phenotypes of HCM, myocardial scarring and 
diffuse fibrosis. Regarding the effects of MMs on phe-
notypic changes in HCM, consideration for assessing 
nDNA and mtDNA mutation load is needed. As shown 
in a previous study related to mitochondrial cardiomyo-
pathy, interstitial and replacement fibrosis is rarely seen 
[10], so the contribution of MMs to myocardial fibrosis 
would be minimal. Although, in our study MM was not 
significantly related to myocardial fibrosis, development 
of potential or hidden endophenotype should be closely 
followed [11, 24].
Regional extracellular space expansion in segments 
without LGE
Even in segments without LGE, ECV was significantly 
higher in patients with SMs. This finding suggests that 
before the development of scarring or replacement fibro-
sis, diffuse interstitial fibrosis develops in this HCM 
group and supports that interstitial fibrosis is a primary 
phenotype in SM-positive HCM. Therefore, regional 
ECV assessment and serial LGE imaging follow-up may 
be suitable for risk stratification in HCM patients. The 
potential mechanism of action may be impaired myo-
cardial flow reserve due to small intramuscular coronary 
artery constriction, but our study did not include the 
stress myocardial perfusion protocol in CMR. Thus, 
future studies on this topic are warranted.
Limitations
Our study had several limitations. Due to our inclu-
sion of a large portion of patients with apical HCM, the 
prevalence of pathogenic SM was low. However, within 
patients without apical HCM, the pathogenic SM rate 
was consistent with other studies. Likewise, the compari-
son between the two major SMs, MYBPC3 and MYH7, 
was not sufficient due to the small sample size. How-
ever, similar to recent results from a multicenter regis-
try [9], we found trend of higher fibrosis in patients with 
the MYH7 mutation than in those with the MYBPC3 
mutation. The ECV value of HCM was slightly higher 
than other studies, it may be due to algorithm of analy-
sis program. However, in this study, all of the patients 
underwent native T1 mapping using the same scanner, 
same protocol, and same analysis program, meaning 
the impact of genetic mutation on ECV would not be 
changed. Finally, only a small number of healthy controls 
were recruited due to significant social limitations at our 
local institution and the need for gadolinium contrast 
phlebotomy for hematocrit. While not ideal, from a prac-
tical standpoint, young people with idiopathic ventricular 
Fig. 3 Comparisons of global %LGE (a), LGE‑involved segment number (b), T2 (c), native T1 (d), post contrast T1 (e), and ECV (f) between sarcomere 
and mitochondria‑related variant groups. SM sarcomere mutation group, MM mitochondria‑related mutation group
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tachycardia and aborted sudden cardiac death became 
part of the de facto control group in this study.
Conclusion
SMs are significantly related to increased myocardial 
fibrosis, even in segments without LGE supporting the 
findings of a worse prognosis in HCM patients with SM. 
Our findings also support that myocardial fibrosis is a 
primary phenotype in patients with SMs. Within non-
SM group, patients with any VUS had higher Doppler 
E/e’ and tendency of higher LGE amount and ECV, which 
supports a previous study results of worse prognosis in 
patients with VUS. Although some patients with HCM 
had pathogenic MMs, they did not exhibit increased 
myocardial fibrosis.
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